Clinical Trial Update: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment [Phase 3]

View source ↗

Summary

A roll-over Phase 3 study is being conducted to collect long-term safety data for everolimus in patients with tuberous sclerosis complex and refractory seizures…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Tuberous Sclerosis Complex

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tuberous Sclerosis Complex | Phase 3 | Status: ACTIVE_NOT_RECRUITING